Answer
Tavlesse (fostamatinib) should not be used in children and adolescents under 18 because adverse reactions affecting actively growing bones were observed in nonclinical studies.
Sources for this answer
- Tavlesse 100 mg film-coated tabletsGrifols UK Ltd · emc · SmPC §4.2 Posology and method of administration · Version 3Document updated
Sources checked